Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz Inc.
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
- Generic Drugs